Promoting Vaccine Equity
The COVID-19 pandemic has brought into sharp relief longstanding equity problems surrounding the allocation of newly developed vaccines.

The COVID-19 pandemic has brought into sharp relief longstanding equity problems surrounding the allocation of newly developed vaccines.

By Timo Minssen, Esther van Zimmeren & Jakob Wested An earlier version of this contribution had been published in Life Science Intellectual Property Review (LSIPR). A voluntary pool or clearinghouse model may give rise to a robust commercial ecosystem for CRISPR and could include special provisions for royalty-free research use by academics. Hence, there may be a path through…